Chronic Lymphocytic Leukemia: New Horizons With BTK Inhibitors: FAQ Part 1

Decera Clinical Education Oncology Podcast · Sep 17, 2020 · 7m

In this episode, Jeff P. Sharman, MD, Danielle M. Brander, MD, and Nicole Lamanna, MD, answer questions focused on the optimizing BTK inhibitor therapy for previously untreated patients with CLL considering presentation characteristics and drug pharmacology.

Presenters:

Jeff P. Sharman, MD, Program Director

Medical Director

Hematology Research

US Oncology Research

Eugene, Oregon

Danielle M. Brander, MD

Assistant Professor of Medicine

Division of Hematologic Malignancies

& Cellular Therapy

Department of Medicine

Duke University

Attending Physician, Hematologic Malignancies

Duke University…